Article
Cell Biology
Qian Li, Chen-Chen Ren, Yan-Nan Chen, Li Yang, Feng Zhang, Bao-Jin Wang, Yuan-Hang Zhu, Fei-Yan Li, Jun Yang, Zhen-An Zhang
Summary: Ovarian cancer is a leading cause of cancer-related death, and the expression of m6A RNA methylation regulators plays a crucial role in patient prognosis. A risk score model based on three selected m6A regulators and a regulatory network of miRNAs-m6A regulators-m6A target genes were found to be valuable in predicting the prognosis of patients with OC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Min Li, Wenli Cheng, Luyun Zhang, Cheng Zhou, Xinyue Peng, Susu Yu, Wenjuan Zhang
Summary: This study explored the role of m6A RNA methylation regulators in Alzheimer's disease (AD) using bioinformatics approaches and identified 14 m6A regulators associated with AD through differential analysis. The study found that dysregulation of m6A methylation affects the occurrence of AD, influences subtype classification, and immune infiltration in AD, with potential targets for m6A regulation identified.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Peilin Cong, Tingmei Wu, Xinwei Huang, Huazheng Liang, Xiaofei Gao, Li Tian, Wanrong Li, Aiwen Chen, Hanxi Wan, Mengfan He, Danqing Dai, Zhen Li, Lize Xiong
Summary: m6A RNA methylation regulators and their targets play crucial roles in the occurrence, progression, and prognosis of glioma. A seven-gene signature including METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA was established and validated, showing a good capability for predicting glioma survival and guiding therapeutic customization and clinical decision-making. The study also identified genes influencing anticancer drug responses, contributing to early phase clinical trials of drug development.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Xin Qing, Qian Chen, Ke Wang
Summary: m6A regulators may play a role in the prevalence of COVID-19 patients. The study identified differentially expressed genes involved in m6A modification and established a random forest model and nomogram to predict the occurrence of COVID-19. Two m6A subtypes were identified using consensus clustering, and patients in one subtype showed activated T-cell functions and potentially better prognosis.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Genetics & Heredity
Bi-Wen Mo, Xiao-Mang Li, Shen-Mei Li, Bo Xiao, Jie Yang, Hui-Min Li
Summary: This study identified m6A genes associated with asthma and proposed DNA methylation-m6A modification gene axes, providing new insights into the pathogenesis of asthma.
Article
Genetics & Heredity
Hao Su, Yutao Wang, Hongjun Li
Summary: RNA N6-methyladenosine (m6A) methylation is a common RNA modification in animals, with significant impacts on RNA metabolism and roles in various cancers. Analysis of prostate cancer datasets from TCGA revealed distinct expression patterns of m6A regulators, with CBLL1, FTO, YTHDC1, HNRNPA2B1 identified as crucial regulators. Knockdown of HNRNPA2B1 showed inhibition of prostate cancer cell migration and invasion, suggesting therapeutic potential.
FRONTIERS IN GENETICS
(2021)
Review
Oncology
Siyi Shen, Jialu Guo, Nengyuan Lv, Qianying Chen, Jinyi Tong
Summary: Endometrial cancer (EC) is one of the most prevalent gynecologic cancers in developed countries, with its incidence increasing worldwide. Recent research has shown that m6A methylation and associated regulators play a critical role in the pathogenesis and progression of EC, providing novel methods for prevention and treatment.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Article
Immunology
Qianqian Zhang, Xiaowei Bao, Mintian Cui, Chunxue Wang, Jinlu Ji, Jiongjie Jing, Xiaohui Zhou, Kun Chen, Lunxian Tang
Summary: This study explored the role of RNA methylation-associated genes (RMGs) in classifying and diagnosing sepsis. By analyzing gene expression profiles, sepsis was classified into three subtypes and five RMGs were identified as biomarkers for sepsis diagnosis. Further validation showed that the expression levels of these five RMGs combined with clinical data could effectively diagnose sepsis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Dayu Kuai, Shengtao Zhu, Haiyun Shi, Ruichuang Yang, Tong Liu, Hui Liu, Li Min, Shutian Zhang
Summary: Through TCGA analysis and immunohistochemistry verification, YTHDF1, IGF2BP1, IGF2BP3, and EIF3B were identified as potential biomarkers of colorectal cancer (CRC), providing significant implications for early diagnosis and strategies for precancerous lesions detection.
Article
Multidisciplinary Sciences
Xincheng Wu, Zhengping Bai
Summary: The study identified three distinct m(6)A modification-related patterns in LUAD patients based on 23 m(6)A regulators. These patterns were associated with immune activation, carcinogenic activation, and substance metabolism. The m(6)Ascore could predict TME infiltration, tumor mutation burden, the effect of tumor immunotherapy, and patient prognosis in LUAD.
SCIENTIFIC REPORTS
(2021)
Article
Medical Laboratory Technology
Yanli Zhang, Yingjie Yang
Summary: The study found that multiple m(6)A RNA methylation regulators were significantly abnormally expressed in endometrial cancer tissue samples. Wilcoxon test showed that age, grade, and risk score were independent risk factors. High FTO expression was associated with worse overall survival.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2021)
Article
Endocrinology & Metabolism
Torunn Ronningen, Mai Britt Dahl, Tone Gretland Valderhaug, Akin Cayir, Maria Keller, Anke Toenjes, Matthias Blueher, Yvonne Boettcher
Summary: The study found that the expression of m6A regulators correlates with obesity, is adipose tissue depot-specific, and related to clinical traits. Genetic variation in m6A regulators adds an additional layer of variability to the functional consequences.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Xiao-hong Mao, Qiang Ye, Guo-bing Zhang, Jin-ying Jiang, Hong-ying Zhao, Yan-fei Shao, Zi-qi Ye, Zi-xue Xuan, Ping Huang
Summary: Aberrant DNA methylation is significantly associated with breast cancer. 23 significant differentially methylated sites, corresponding to 9 different genes, were identified in breast cancer datasets. High expression of selected methylation genes was strongly predictive for breast cancer diagnosis and prognosis.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Cell Biology
Huaying Zhao, Yue Xu, Yilin Xie, Lan Zhang, Ming Gao, Shenglei Li, Feng Wang
Summary: This study revealed that aberrations in m6A regulators are closely associated with prognosis in esophageal cancer, with some regulators significantly correlated to disease severity and poor outcomes. The levels of m6A regulators are also related to the expression of immune regulators and immune infiltration levels in EC, suggesting their involvement in tumor progression through RNA binding and cell proliferation regulation.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Medicine, Research & Experimental
Lu Chen, Ying He, Jinyu Zhu, Shujuan Zhao, Shasha Qi, Xudong Chen, Hao Zhang, Ziheng Ni, Yuan Zhou, Gongxing Chen, Shuiping Liu, Tian Xie
Summary: N6-methyladenosine (m6A), the most common internal modification in RNA, can be regulated by three types of regulators, including methyltransferases (writers), demethylases (erasers), and m6A binding proteins (readers). It has been shown that m6A RNA methylation affects cancer immunity in various cancers and can be used as predictors of cancer diagnosis and prognosis. This article summarizes the regulation of m6A regulators on mRNA expression, their roles in inflammation, immunity, and immunotherapy, the impact of m6A modification on tumor microenvironment and immune response, and the potential of m6A methylation regulators as therapeutic targets in cancer immunity.
BIOMEDICINE & PHARMACOTHERAPY
(2023)